144
Participants
Start Date
July 31, 2007
Primary Completion Date
July 31, 2010
Study Completion Date
December 31, 2011
Forodesine 200 mg
2 x 100mg tablets once daily
Wien, Vienna
Cabrini Hospital, Malvern
Torino, Torino
Upstate Medical University, Syracuse
Hillman Cancer Ctr., University of Pittsburgh, Pittsburgh
Hospital at the University of Pennsylvania, Philadelphia
Milan, Milan
Universitat Kiel, Kiel
Wake Forest University Health Sceinces, Dept. of Dermatology, Winston-Salem
Duke University Medical Center, Durham
Madrid, Madrid
Emory University, Atlanta
Toulouse, Toulouse
Pessac, Pessac
Moffitt Cancer Center, Tampa
Montpellier, Montpellier
Bologna, Bologna
University Hospitals Case Medical Center, Dept. of Dermatology, Cleveland
Gabrail Cancer Center, Canton
Firenze, Florence
CHU Robert Debre, Reims
University of Wisconsin-Madison, Dept of Dermatology, Madison
Hopital Hotel-Dieu, Clermont-Ferrand
Washington University School of Medicine, St Louis
Klinik fur Dermatologie, Venerologie und Allergologie, Mannheim
LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport
M.D. Anderson Cancer Center - Dermatology, Houston
Seattle Cancer Care Alliance, Seattle
Creteil, Créteil
Stanford University Medical Center, Stanford
University of Alabama at Birmingham, Comprehensive Cancer Ctr, Birmingham
Yale Cancer Center, New Haven
Boston Medical Center, Boston
Hackensack University Medical Ctr, Hackensack
Helsinki, Helsinki
Campus Charité Mitte, Berlin
Universitatsklinikum Jena, Jena
Rome, Rome
Zurich, Zurich
London, London
Manchester, Manchester
Lead Sponsor
BioCryst Pharmaceuticals
INDUSTRY